Hereditary breast cancer / Posted 2 years ago

Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neoadjuvant 5- Fluorouracil, Epirubicin and Cyclophosphamide vs Docetaxel and Cyclophosphamide chemotherapy (ROSCO)

Doctors often give chemotherapy first to help shrink tumours before surgery for breast cancer. If you have invasive breast cancer you might be offered a combination of drugs that includes a taxane such as docetaxel (also called Taxotere). Or you might have combination that includes an anthracycline such as epirubicin.

At the moment, doctors usually give both drugs one after the other. These drugs work in different ways to kill cancer cells. For some people epirubicin works well and for other people docetaxel works well. But doctors aren’t sure which drugs work best for which people. All drugs have side effects and doctors don’t want to give drugs that people don’t need.

In this trial, researchers are looking at 2 new tests. The tests are called CEP17 and TOP2A. They may help doctors to work out who benefits most from having epirubicin or who would benefit from having docetaxel.
The aims of the trial are to find out

  • How well the tests work in showing who will benefit from having a taxane and who will benefit from having an anthracycline
  • More about quality of life
  • Inclusion Criteria : please see link to CRUK website
  • Exclusion Criteria : please see link to CRUK website
  • Study start date : 07/10/2015
  • Study end date : 31/03/2021
  • Wales-Based Study Contact : Colette Kempt

No post found